State Street Multi-Asset Real Return ETF

SPDR SSgA Multi-Asset Real Return ETF $RLY Stock Acquired by Gibbs Wealth Management

Gibbs Wealth Management boosted its position in SPDR SSgA Multi-Asset Real Return ETF (NYSEARCA:RLY) by 19.8% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 168,453 shares of the company's stock after acquiring an additional 27,785 shares

Why Midterm Gridlock Favors Sector ETFs

Prediction markets point to a divided Congress after November's midterm elections: Democrats retaking the House, Republicans holding the Senate. Key Takeaways: A divided Congress after the midterms may limit big legislation but not targeted policy moves.

State Street Real Return ETF (RLY) Touches New 52-Week High

State Street Multi-Asset Real Return ETF hits a 52-week high as inflation concerns, easing policy expectations and real assets support gains.

Bank of America Corp DE Boosts Holdings in SPDR SSgA Multi-Asset Real Return ETF $RLY

2025 Was a Record Year for ETFs; 2026 Is Upstaging It

After a record-breaking 2025, the 2026 ETF market climbs to $1.2T in year-to-date inflows. We breakdown where investor demand is flowing.

Inflation Isn't Gone Yet: Give Real Asset ETFs a Chance

Considering that the Federal Reserve has been meeting this week, it's safe to say that inflation is likely front-and-center on the minds of many advisors and investors. After all, energy prices and supply chain constraints have kept inflationary pressures far more persistent than the Fed would like.

26,275 Shares in SPDR SSgA Multi-Asset Real Return ETF $RLY Acquired by Compound Planning Inc.

Shareholder Alert: Ademi LLP investigates whether Rallybio Corporation is obtaining a Fair Price for Public Shareholders

MILWAUKEE, June 2, 2026 /PRNewswire/ -- Ademi LLP is investigating Rallybio (Nasdaq: RLY) for possible breaches of fiduciary duty and other violations of law in its recently announced transaction with Avenzo Therapeutics. Click here to learn how to join our investigation and obtain additional information or contact us at gademi@ademilaw.com or toll-free: 866-264-3995.